Listen Score
LS 51
Global Rank
TOP 0.5%

ABOUT THIS PODCAST 🔗

Update frequency:
weekly
Average audio length:
62 minutes
Guest interviews
Has sponsors
English
United States
380 episodes
since Jan. 22, 2017
episodic
explicit content

AUDIENCE OF THIS PODCAST 🔗

~75.37% of listeners are from United States.
🇺🇸
US
75.37%
🇨🇦
CA
3.98%
🇦🇺
AU
2.84%
🇬🇧
GB
2.49%
🇩🇪
DE
1.53%
🇮🇪
IE
1.34%
🇳🇱
NL
0.91%
🇪🇸
ES
0.87%
🇫🇷
FR
0.73%
🇫🇮
FI
0.64%
🇸🇬
SG
0.58%
🇰🇪
KE
0.53%
🇱🇾
LY
0.49%
🇰🇷
KR
0.47%
🇳🇿
NZ
0.40%
🇩🇰
DK
0.37%
🇸🇪
SE
0.36%
🇮🇳
IN
0.36%
🇮🇩
ID
0.33%
🇨🇭
CH
0.33%
🇯🇵
JP
0.29%
🇲🇽
MX
0.28%
🇧🇪
BE
0.26%
🇪🇬
EG
0.25%
🇷🇺
RU
0.24%
🇿🇦
ZA
0.22%
🇵🇰
PK
0.21%
🇳🇴
NO
0.20%
🇹🇼
TW
0.17%
🇸🇦
SA
0.16%
🇵🇪
PE
0.16%
🇩🇿
DZ
0.13%
🇵🇱
PL
0.12%
🇭🇰
HK
0.12%
🇮🇸
IS
0.10%
🇧🇼
BW
0.10%
🇮🇹
IT
0.10%
Others
1.97%
* Data source: directly measured on Listen Notes. real-time

LATEST EPISODE 🔗

In this episode of The Psychedelic Podcast, Paul F. Austin sits down with Mira Funk, LCSW, a Harvard-educated psychotherapist and the founder of Unjourneying, a private practice built around 5-MeO-DMT, N,N-DMT, and salvia divinorum. This episode is sponsored by Mira Funk. Mira traces her path fro…

SEARCH PAST EPISODES

Search past episodes of The Psychedelic Podcast.

PREVIOUS EPISODES

Paul talks with biohacking pioneer Dave Asprey about medicalization, microdosing, consciousness, and Dave's new BEYOND Wonderland psychedelics conference in Austin. In this bonus episode, Paul welcomes back Dave Asprey, founder of Bulletproof Coffee and creator of the biohacking movement, to talk …
In this episode of The Psychedelic Podcast, Paul F. Austin speaks with computer scientist, climate investor, and Nexus author Ramez Naam about psychedelics, AI, neurotechnology, and cognitive liberty. Find full show notes and links here: https://thethirdwave.co/podcast/episode-374/?ref=278 Ramez …
In this episode of The Psychedelic Podcast, Paul F. Austin speaks with therapist and InnerEthics® founder Kylea Taylor about why responsible psychedelic therapy requires more than good intentions. Find full show notes and links here: https://thethirdwave.co/podcast/episode-373/?ref=278 Kylea expl…
In this episode of The Psychedelic Podcast, Paul F. Austin speaks with Paije Alexandra West, founder of ETÉREO, about iboga, ibogaine, and Bwiti initiation. Drawing on Paul's recent retreat experience at ETÉREO in Baja, they examine what can be lost when iboga is reduced to a clinical alkaloid an…
In this episode of The Psychedelic Podcast, Paul F. Austin speaks with psychiatrist and TaperClinic founder Dr. Josef Witt-Doerring about antidepressant withdrawal, psychiatric deprescribing, and psychedelic readiness. Find full show notes and links here: https://thethirdwave.co/podcast/episode-37…
In this episode of The Psychedelic Podcast, Paul F. Austin speaks with investigative journalist Robert Whitaker about the evidence behind psychiatric prescribing, SSRI withdrawal, and what psychedelic medicine can learn from that history. Find full show notes and links here: https://thethirdwave.c…
In this episode of The Psychedelic Podcast, Paul F. Austin welcomes Dr. Remi Drozd back to explore ketamine, SSRIs, and the changing landscape of psychedelic mental health care. Find full show notes and links here: https://thethirdwave.co/podcast/episode-369/?ref=278 Since Remi first appeared on …
In this episode of The Psychedelic Podcast, Paul F. Austin speaks with Dr. Richard Louis Miller about what psychedelic medicine must get right as it moves toward broader acceptance. Richard explains why transparent reporting of adverse effects is essential to informed choice, where research still l…
In this episode of The Psychedelic Podcast, Paul F. Austin speaks with Ian Gardner, founder and CEO of The Acraya, about dark retreats as an ancient contemplative practice now entering Western culture. This episode is sponsored by The Acraya. Listeners of The Psychedelic Podcast can receive 5% of…
Disclaimer: The podcast and artwork embedded on this page are from Third Wave, which is the property of its owner and not affiliated with or endorsed by Listen Notes, Inc.